Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
Prime Minister Shinzo Abe’s Cabinet signed off on economic and fiscal policy guidelines on June 30, which enshrined a new generic share target of 80% along with pledges to spur innovation in the pharmaceutical arena. The guidelines spelled out that…
To read the full story
Related Article
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- Z2 Rule, DPC Incentive Need Revisions in Line with New Generic Target: MOF Budget Examiner
July 22, 2015
- NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
- FPMAJ Chair Hails Innovation-Fueling Policies in Govt Fiscal Plan
July 2, 2015
- LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
- LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
- 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
- Shiozaki’s Pitch on 80% Generic Target by FY2020 Fails to Resonate
June 11, 2015
- MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
- Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
REGULATORY
- Lower House Health Committee OKs Bill to Amend PMD Act, Adopts Supplementary Resolution
April 17, 2025
- MHLW Provides Draft Policymaking Document for Off-Year Revision after Opposition’s Call
April 17, 2025
- MHLW Looking into Impact of US Tariffs, Seeks Drug Makers’ Support
April 17, 2025
- MHLW to Revise Patent Linkage Scheme in FY2025, Create Expert Committee
April 16, 2025
- LDP’s Pharma Study Group Likely to Stay Even after Its Chair Bows Out
April 16, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…